Oral Session 1-10C AML: FLT3 Inhibitors

[OS1-10C-1] Gilteritinib prolongs survival in patients with FLT3-mutated R/R AML: phase 3 ADMIRAL trial results

Hisayuki Yokoyama¹, Nobuyuki Aotsuka², Kiyoshi Ando³, Hiroatsu Iida⁴, Takayuki Ishikawa⁵, Kensuke Usuki⁶, Masahiro Onozawa⁷, Masahiro Kizaki⁸, Kohmei Kubo⁹, Junya Kuroda¹⁰, Yukio Kobayashi¹¹, Takayuki Shimizu¹², Shigeru Chiba¹³, Miho Nara¹⁴, Tomoko Hata¹⁵, Michihiro Hidaka¹⁶, Shinichiro Fujiwara¹⁷, Naoko Hosono¹⁸, Yoshinobu Maeda¹⁹, Yasuyoshi Morita²⁰, Mikiko Kusano²¹, Qiaoyang Lu²², Shuichi Miyawaki²³, Erkut Bahceci²², Tomoki Naoe²⁴ (1.Sendai Medical Center, Sendai, Japan, 2.Japanese Red Cross Narita Hospital, Narita, Japan, 3.Tokai University School of Medicine, Isehara, Japan, 4.NHO Nagoya Medical Center, Nagoya, Japan, 5.Kobe City Medical Center General Hospital, Kobe, Japan, 6.NTT Medical Center Tokyo, Tokyo, Japan, 7.Hokkaido University, Sapporo, Japan, 8.Saitama Medical Center, Saitama Medical University, Kawagoe, Japan, 9.Aomori Prefectural Central Hospital, Aomori, Japan, 10.Kyoto Prefectural University of Medicine, Kyoto, Japan, 11.International University of Health and Welfare, Mita Hospital, Tokyo, Japan, 12.Keio University School of Medicine, Tokyo, Japan, 13.University of Tsukuba, Tsukuba, Japan, 14.Akita University, Akita, Japan, 15.Nagasaki University, Nagasaki, Japan, 16.Kumamoto Medical Center, Kumamoto, Japan, 17.Jichi Medical University, Shimotsuke, Japan, 18.University of Fukui, Fukui, Japan, 19.Okayama University Hospital, Okayama, Japan, 20.Kindai University, Osaka, Japan, 21.Astellas Pharma, Inc., Tokyo, Japan, 22.Astellas Pharma US, Inc., Northbrook, IL, USA, 23.Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan, 24.NHO Nagoya Medical Center, Nagoya, Japan)